These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38796779)

  • 61. Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis.
    Tanabe J; Watanabe N; Endo A; Nagami T; Inagaki S; Tanabe K
    Intern Med; 2021 Feb; 60(4):569-573. PubMed ID: 33028770
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series.
    Vicino A; Hottinger AF; Latifyan S; Boughdad S; Becce F; Prior JO; Kuntzer T; Brouland JP; Dunet V; Obeid M; Théaudin M
    J Neurol; 2024 Apr; 271(4):1947-1958. PubMed ID: 38141128
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Immune checkpoint inhibitor-induced anti-striational antibodies in myasthenia gravis and myositis: a case report].
    Sugiyama Y; Esa Y; Watanabe A; Kobayashi J; Suzuki S; Takahashi D
    Rinsho Shinkeigaku; 2021 Sep; 61(9):630-634. PubMed ID: 34433744
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pembrolizumab-induced peripheral nervous system damage: A combination of myositis/ myasthenia overlap syndrome and motor axonal polyneuropathy.
    Arman Ç; Ibrahim K; Elif OK; Hacer D; Yeşim P
    Ideggyogy Sz; 2023 Nov; 76(11-12):422-426. PubMed ID: 38051685
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
    Diamanti L; Picca A; Bini P; Gastaldi M; Alfonsi E; Pichiecchio A; Rota E; Rudà R; Bruno F; Villani V; Galiè E; Vogrig A; Valente M; Zoccarato M; Poretto V; Giometto B; Cimminiello C; Del Vecchio M; Marchioni E
    Neurol Sci; 2022 Mar; 43(3):2031-2041. PubMed ID: 34424427
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review.
    Bai J; Li D; Yang P; Xu K; Wang Y; Li Q; Liu J; Du W; Zhang F; Feng R
    Front Oncol; 2021; 11():778185. PubMed ID: 35047395
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Presence of Multiple Autoimmune Antibodies Involved in Concurrent Myositis and Myocarditis and Myasthenia Gravis Without Thymoma: A Case Report.
    Zhou Z; Chen X; Liu G; Pu J; Wu J
    Front Neurol; 2019; 10():770. PubMed ID: 31379720
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia.
    Takamatsu K; Nakane S; Suzuki S; Kosaka T; Fukushima S; Kimura T; Miyashita A; Mukaino A; Yamakawa S; Watanabe K; Jinnin M; Komohara Y; Ihn H; Ando Y
    Ann Clin Transl Neurol; 2018 Nov; 5(11):1421-1427. PubMed ID: 30480036
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Novel use of abatacept and ruxolitinib as salvage therapy in steroid-refractory immune checkpoint blockade-induced myocarditis with myasthenia and myositis overlap syndrome.
    Byer SH; Stewart C; Mansour S; Grewal US
    Eur J Cancer; 2024 May; 202():114027. PubMed ID: 38507971
    [No Abstract]   [Full Text] [Related]  

  • 70. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis.
    Cautela J; Zeriouh S; Gaubert M; Bonello L; Laine M; Peyrol M; Paganelli F; Lalevee N; Barlesi F; Thuny F
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298621
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Case Report: Orbital Myositis and Myasthenia Gravis as Symptoms of Immune Reconstitution Inflammatory Syndrome in a Patient With Human Immunodeficiency Virus Infection.
    Wang Y; Zhao N; Yang J; Wen Y
    Front Immunol; 2020; 11():595068. PubMed ID: 33381117
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sintilimab-Induced Myocarditis Overlapping Myositis in a Patient With Metastatic Thymoma: A Case Report.
    Yang ZX; Chen X; Tang SQ; Zhang Q
    Front Cardiovasc Med; 2021; 8():797009. PubMed ID: 35004910
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
    Leaver PJ; Jang HS; Vernon ST; Fernando SL
    BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Durvalumab-Induced Triple-M Syndrome.
    Adeoye FW; Jaffar N; Surandran S; Begum G; Islam MR
    Eur J Case Rep Intern Med; 2024; 11(8):004729. PubMed ID: 39130070
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.
    Moreira A; Loquai C; Pföhler C; Kähler KC; Knauss S; Heppt MV; Gutzmer R; Dimitriou F; Meier F; Mitzel-Rink H; Schuler G; Terheyden P; Thoms KM; Türk M; Dummer R; Zimmer L; Schröder R; Heinzerling L
    Eur J Cancer; 2019 Jan; 106():12-23. PubMed ID: 30453170
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Life-threatening immune checkpoint inhibitor-induced myocarditis and myasthenia gravis overlap syndrome treated with abatacept: a case report.
    Wakefield C; Shultz C; Patel B; Malla M
    BMJ Case Rep; 2021 Nov; 14(11):. PubMed ID: 34728505
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immune checkpoint inhibitor therapy: A double-edged sword?
    Kim HJ; Evoli A
    Neurology; 2017 Sep; 89(11):1101-1102. PubMed ID: 28821690
    [No Abstract]   [Full Text] [Related]  

  • 78. Checkpoint inhibitor myasthenia-like syndrome and myositis associated with extraocular muscle atrophy.
    Ozarczuk TRA; Prentice DA; Kho LK; vanHeerden J
    J Clin Neurosci; 2020 Jan; 71():271-272. PubMed ID: 31889642
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.
    Kao JC; Brickshawana A; Liewluck T
    Curr Neurol Neurosci Rep; 2018 Aug; 18(10):63. PubMed ID: 30078154
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors.
    Kaira K; Mouri A; Imai H; Yamaguchi O; Kagamu H
    Curr Oncol Rep; 2024 Sep; 26(9):1113-1119. PubMed ID: 38954314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.